ADMA on Nasdaq
ADMA Biologics (United States)
Company in Ramsey, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Tarsus Pharmaceuticals, Inc., Immunocore Holdings plc or Krystal Biotech, Inc., or pick any stock.
- TickerADMA on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersRamsey1
- Websitewww.admabiologics.com
- Incorporated inDE3
- Business addressC/O Adma Biologics, Inc., 465 State Route 17, Ramsey, Nj 074463
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
57.4%Gross margin5
37.5%Operating margin5
28.8%Net margin5
19.6%Revenue growth, 20255
30.8%Return on equity5
0.15×Debt to equity5
$27.8MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
ADMABio Manufacturing brought in 97% of the revenue ADMA Biologics (United States) broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| ADMABio Manufacturing | $249.7M | $415.8M | $493.0M |
| Plasma Collection Centers | $8.3M | $10.5M | $17.0M |
Regions
United States brought in 99% of the revenue ADMA Biologics (United States) broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $244.9M | $410.1M | $504.1M |
| Outside the United States | $13.3M | $16.3M | $6.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue43¢$217.4M
- Research and development1¢$4.8M
- Selling, general and admin18¢$91.6M
- Other costs3¢$13.8M
- Income tax7¢$35.7M
- Profit29¢$146.9M
Out of $510.2M in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Capital spending41¢$22.6M
- Share buybacks59¢$31.9M
Out of $50.4M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| REVENUES | $510.2M | $426.5M | $258.2M |
| Cost of product revenue | $217.4M | $206.9M | $169.3M |
| Gross profit | $292.8M | $219.6M | $88.9M |
| Research and development | $4.8M | $1.8M | $3.3M |
| Plasma center operating expenses | $4.8M | $4.2M | $4.3M |
| Amortization of intangible assets | $144.0K | $388.0K | $724.0K |
| Selling, general and administrative | $91.6M | $74.1M | $59.0M |
| Total operating expenses | $101.3M | $80.6M | $67.3M |
| INCOME FROM OPERATIONS | $191.4M | $139.0M | $21.6M |
| Interest income | $1.9M | $2.1M | $1.6M |
| Interest expense | -$7.1M | -$13.9M | -$25.0M |
| Loss on extinguishment of debt | -$3.3M | -$1.2M | -$26.2M |
| Other expense | -$212.0K | -$193.0K | -$287.0K |
| Other expense, net | -$8.8M | -$13.3M | -$49.9M |
| INCOME (LOSS) BEFORE INCOME TAXES | $182.7M | $125.7M | -$28.2M |
| Income tax expense (benefit) | $35.7M | -$72.0M | $0 |
| NET INCOME (LOSS) | $146.9M | $197.7M | -$28.2M |
| BASIC EARNINGS (LOSS) PER COMMON SHARE (in Dollars per share) | $0.62 | $0.85 | -$0.13 |
| DILUTED EARNINGS (LOSS) PER COMMON SHARE (in Dollars per share) | $0.60 | $0.81 | -$0.13 |
| Basic (in Shares) | 238.3M shares | 233.1M shares | 224.0M shares |
| Diluted (in Shares) | 244.9M shares | 243.3M shares | 224.0M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $87.6M | $103.1M | |
| Accounts receivable, net | $158.4M | $50.0M | |
| Inventories, net | $206.5M | $170.2M | |
| Prepaid expenses and other current assets | $7.5M | $8.0M | |
| Assets held for sale | $6.5M | $0 | |
| Total current assets | $466.5M | $331.4M | |
| Property and equipment, net | $65.1M | $54.7M | |
| Intangible assets, net | $632.0K | $460.0K | |
| Goodwill | $3.5M | $3.5M | |
| Deferred tax assets, net | $73.3M | $84.3M | |
| Right-of-use assets | $6.7M | $8.6M | |
| Deposits and other assets | $8.6M | $5.7M | |
| TOTAL ASSETS | $624.2M | $488.7M | $329.2M |
| Accounts payable | $22.5M | $20.2M | |
| Accrued expenses and other current liabilities | $40.5M | $34.1M | |
| Current portion of long-term debt | $2.8M | $0 | |
| Current portion of lease obligations | $1.1M | $1.2M | |
| Liabilities held for sale | $2.6M | $0 | |
| Total current liabilities | $69.5M | $55.5M | |
| Long-term debt | $69.3M | $72.3M | |
| Deferred revenue, net of current portion | $1.4M | $1.5M | |
| End of term fee | $0 | $1.3M | |
| Lease obligations, net of current portion | $6.6M | $8.6M | |
| Other non-current liabilities | $0 | $360.0K | |
| TOTAL LIABILITIES | $146.9M | $139.7M | |
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding | $0 | $0 | |
| Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, December 31, 2025: 239,793,566 issued and 237,874,496 outstanding; December 31, 2024: 236,620,545 issued and outstanding | $24.0K | $24.0K | |
| Treasury stock, at cost, 1,919,070 and 0 shares as of December 31, 2025 and December 31, 2024, respectively | -$32.1M | $0 | |
| Additional paid-in capital | $671.0M | $657.6M | |
| Accumulated deficit | -$161.7M | -$308.6M | |
| TOTAL STOCKHOLDERS EQUITY | $477.3M | $349.0M | $135.2M |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $624.2M | $488.7M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in Shares) | 239.8M shares | 236.6M shares | |
| Common stock, shares outstanding (in Shares) | 237.9M shares | 236.6M shares | |
| Treasury stock (in Shares) | 1.9M shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $146.9M | $197.7M | -$28.2M |
| Depreciation and amortization | $8.1M | $8.0M | $8.3M |
| Loss on disposal of fixed assets | $9.0K | $106.0K | $182.0K |
| Deferred income tax provision | $11.0M | -$84.3M | $0 |
| Interest paid in kind | $0 | $0 | $3.8M |
| Stock-based compensation | $20.0M | $13.6M | $6.2M |
| Amortization of debt discount | $717.0K | $951.0K | $2.6M |
| Loss on extinguishment of debt | $3.3M | $1.2M | $26.2M |
| Amortization of license revenue | -$143.0K | -$143.0K | -$143.0K |
| Accounts receivable | -$108.4M | -$22.6M | -$11.9M |
| Inventories | -$36.2M | $2.7M | -$9.6M |
| Prepaid expenses and other current assets | -$1.5M | -$2.7M | -$239.0K |
| Deposits and other assets | $279.0K | $15.0K | $1.1M |
| Accounts payable | $2.3M | $4.2M | $3.8M |
| Accrued expenses | $5.2M | $1.0M | $7.5M |
| Other current and non-current liabilities | -$1.2M | -$1.1M | -$791.0K |
| Net cash provided by operating activities | $50.4M | $118.7M | $8.8M |
| Purchase of property and equipment | -$22.6M | -$8.2M | -$4.8M |
| Acquisition of intangible assets | -$316.0K | -$349.0K | -$210.0K |
| Deposit received on net assets held for sale | $1.0M | $0 | $0 |
| Net cash used in investing activities | -$21.9M | -$8.6M | -$5.0M |
| Prepayment penalties on repayment of debt | -$1.0M | -$450.0K | -$11.1M |
| Proceeds from issuance of note payable | $0 | $0 | $135.0M |
| Taxes paid on vested restricted stock units | -$9.5M | -$5.0M | -$1.4M |
| Payments on finance lease obligations | $0 | $0 | -$17.0K |
| Debt issuance costs | -$2.2M | $0 | $0 |
| Net proceeds from the exercise of stock options | $3.0M | $7.5M | $1.1M |
| Payment of end of term fee | -$1.3M | -$375.0K | -$1.6M |
| Payment of deferred financing fees | $0 | $0 | -$2.4M |
| Acquisition of treasury stock | -$31.9M | $0 | $0 |
| Net cash used in financing activities | -$44.0M | -$58.3M | -$39.0M |
| Net (decrease) increase in cash and cash equivalents | -$15.5M | $51.8M | -$35.2M |
Former names
- R&R ACQUISITION VI, INCJul 10, 2006 to Feb 21, 20123
Recent filings
- Aug 7, 2026SCHEDULE 13G
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 28, 20264
- Jul 17, 20264
- Jun 2, 20268-K
- May 28, 20264
- May 14, 20264
- May 12, 20264
- May 6, 20268-K
- May 6, 202610-Q
- May 4, 20268-K
- Apr 29, 2026SCHEDULE 13G
- Apr 15, 2026DEF 14A
- Apr 15, 2026DEFA14A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.admabiologics.com1
- WikidataQ30260263
- SEC EDGARCIK 1368514
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4Company websiteADMA Biologics (United States) photo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13